CT screening for lung cancer: Is the evidence strong enough?

Lung Cancer

Volumn 91, Issue , 2016, Pages 29-35

  Field, J K ^a   Devaraj, A ^b   Duffy, S W ^c   Baldwin, D R ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Low dose computed tomography; Lung cancer screening; Mortality cost effectiveness; Recruitment risk modelling; Smoking cessation; Volumetric analysis of CT scans

Indexed keywords

CANCER MORTALITY; CANCER SCREENING; CODING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; EUROPE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; LUNG CANCER; MEDICARE; PATIENT REFERRAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SMOKING CESSATION; UNITED STATES; AGED; EARLY CANCER DIAGNOSIS; FEMALE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROCEDURES; STANDARDS;

AGED; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; UNITED STATES;

EID: 84955158062     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.11.003     Document Type: Review

References (48)

1. O'Dowd E.L., McKeever T.M., Baldwin D.R., Anwar S., Powell H.A., Gibson J.E., Iyen-Omofoman B., Hubbard R.B. What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK?. Thorax 2015, 70:161-168.
2. Marteau T.M., Mantzari E. Public health: the case for pay to quit. Nature 2015, 523:40-41.
3. van der Aalst C.M., van den Bergh K.A., Willemsen M.C., de Koning H.J., van Klaveren R.J. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. Thorax 2010, 65:600-605.
4. Land S.R., Marcus P.M. Cancer screening and diagnosis: opportunities for smoking cessation intervention. J. Clin. Oncol. 2015, 33:1631-1632.
5. Aberle D.R., DeMello S., Berg C.D., Black W.C., Brewer B., Church T.R., Clingan K.L., Duan F., Fagerstrom R.M., Gareen I.F., et al. Results of the two incidence screenings in the National Lung Screening Trial. N. Engl. J. Med. 2013, 369:920-931.
6. Aberle D.R., Berg C.D., Black W.C., et al. The National Lung Screening Trial: overview and study design. Radiology 2011, 258:243-253.
7. Field J.K., Smith R.A., Aberle D.R., Oudkerk M., Baldwin D.R., Yankelevitz D., Pedersen J.H., Swanson S.J., Travis W.D., Wisbuba I.I., et al. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J. Thorac. Oncol. 2012, 7:10-19.
8. Field J.K., Hansell D.M., Duffy S.W., Baldwin D.R. CT screening for lung cancer: countdown to implementation. Lancet Oncol. 2013, 14:e591-e600.
9. Humphrey L.L., Deffebach M., Pappas M., Baumann C., Artis K., Mitchell J.P., Zakher B., Fu R., Slatore C.G. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann. Intern. Med. 2013, 159:411-420.
10. Kovalchik S.A., Tammemagi M., Berg C.D., Caporaso N.E., Riley T.L., Korch M., Silvestri G.A., Chaturvedi A.K., Katki H.A. Targeting of low-dose CT screening according to the risk of lung-cancer death. N. Engl. J. Med. 2013, 369:245-254.
11. Tammemagi M.C., Church T.R., Hocking W.G., Silvestri G.A., Kvale P.A., Riley T.L., Commins J., Berg C.D. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014, 11:e1001764.
12. Baldwin D.R., Duffy S.W., Wald N.J., Page R., Hansell D.M., Field J.K. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax 2011, 66:308-313.
13. Cassidy A., Myles J.P., van Tongeren M., Page R.D., Liloglou T., Duffy S.W., Field J.K. The LLP risk model: an individual risk prediction model for lung cancer. Br. J. Cancer 2008, 98:270-276.
14. McRonald F.E., Yadegarfar G., Baldwin D.R., Devaraj A., Brain K.E., Eisen T., Holemans J.A., Ledson M., Screaton N., Rintoul R.C., et al. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev. Res. (Phila.) 2014, 7:362-371.
15. Field J.K., Devaraj A., Baldwin D.R., Holemans J., Screaton N., Ledson M., Rintoul R.C., Nair A., Gosney J.R., Rassl D., et al. UK lung Cancer Screening trial (UKLS): prevalence data at baseline. Lung Cancer 2014, 83:S24-S25.
16. National Lung Screening Trial Research T., Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., Sicks J.D. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 2011, 365:395-409.
17. van Klaveren R.J., Oudkerk M., Prokop M., Scholten E.T., Nackaerts K., Vernhout R., van Iersel C.A., van den Bergh K.A., van't Westeinde S., van der Aalst C., et al. Management of lung nodules detected by volume CT scanning. N. Engl. J. Med. 2009, 361:2221-2229.
18. Horeweg N., van der Aalst C.M., Thunnissen E., Nackaerts K., Weenink C., Groen H.J., Lammers J.W., Aerts J.G., Scholten E.T., van Rosmalen J., et al. Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. Am. J. Respir. Crit. Care Med. 2013, 187:848-854.
19. Mettler F.A., Huda W., Yoshizumi T.T., Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008, 248:254-263.
20. Van't Westeinde S.C., van Klaveren R.J. Screening and early detection of lung cancer. Cancer J. 2011, 17:3-10.
21. Heuvelmans M.A., Oudkerk M., de Bock G.H., de Koning H.J., Xie X., van Ooijen P.M., Greuter M.J., de Jong P.A., Groen H.J., Vliegenthart R. Optimisation of volume-doubling time cutoff for fast-growing lung nodules in CT lung cancer screening reduces false-positive referrals. Eur. Radiol. 2013, 23:1836-1845.
22. Horeweg N., Scholten E.T., de Jong P.A., van der Aalst C.M., Weenink C., Lammers J.W., Nackaerts K., Vliegenthart R., Ten Haaf K., Yousaf-Khan U.A., et al. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. Lancet Oncol. 2014, 15:1342-1350.
23. Callister M.E., Baldwin D.R., Akram A.R., Barnard S., Cane P., Draffan J., Franks K., Gleeson F., Graham R., Malhotra P., et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax 2015, 70(Suppl. 2):ii1-ii54.
24. McWilliams A., Tammemagi M.C., Mayo J.R., Roberts H., Liu G., Soghrati K., Yasufuku K., Martel S., Laberge F., Gingras M., et al. Probability of cancer in pulmonary nodules detected on first screening CT. N. Engl. J. Med. 2013, 369:910-919.
25. Horeweg N., van Rosmalen J., Heuvelmans M.A., van der Aalst C.M., Vliegenthart R., Scholten E.T., Ten Haaf K., Nackaerts K., Lammers J.W., Weenink C., et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol. 2014, 15:1332-1341.
26. Horeweg N., van der Aalst C.M., Vliegenthart R., Zhao Y., Xie X., Scholten E.T., Mali W., Thunnissen E., Weenink C., Groen H.J., et al. Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur. Respir. J. 2013, 42:1659-1667.
27. Herder G.J., van Tinteren H., Golding R.P., Kostense P.J., Comans E.F., Smit E.F., Hoekstra O.S. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest 2005, 128:2490-2496.
28. Brunelli A., Charloux A., Bolliger C.T., Rocco G., Sculier J.P., Varela G., Licker M., Ferguson M.K., Faivre-Finn C., Huber R.M., et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur. Respir. J. 2009, 34:17-41.
29. Lim E., Baldwin D., Beckles M., Duffy J., Entwisle J., Faivre-Finn C., Kerr K., Macfie A., McGuigan J., Padley S., et al. Guidelines on the radical management of patients with lung cancer. Thorax 2010, 65(Suppl. 3):iii1-iii27.
30. Okami J., Ito Y., Higashiyama M., Nakayama T., Tokunaga T., Maeda J., Kodama K. Sublobar resection provides an equivalent survival after lobectomy in elderly patients with early lung cancer. Ann. Thorac. Surg. 2010, 90:1651-1656.
31. Billmeier S.E., Ayanian J.Z., Zaslavsky A.M., Nerenz D.R., Jaklitsch M.T., Rogers S.O. Predictors and outcomes of limited resection for early-stage non-small cell lung cancer. J. Natl. Cancer Inst. 2011, 103:1621-1629.
32. Schuchert M.J., Abbas G., Awais O., Pennathur A., Nason K.S., Wilson D.O., Siegfried J.M., Luketich J.D., Landreneau R.J. Anatomic segmentectomy for the solitary pulmonary nodule and early-stage lung cancer. Ann. Thorac. Surg. 2012, 93:1786-1787. discussion 1780-1787.
33. Bao F., Ye P., Yang Y., Wang L., Zhang C., Lv X., Hu J. Segmentectomy or lobectomy for early stage lung cancer: a meta-analysis. Eur. J. Cardiothorac. Surg. 2014, 46:1-7.
34. Verstegen N., Oosterhuis J., Palma D., Rodrigues G., Lagerwaard F., van der Elst A., Mollema R., van Tets W., Warner A., Joosten J. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann. Oncol. 2013, 24:1543-1548.
35. Saghir Z., Dirksen A., Ashraf H., Bach K.S., Brodersen J., Clementsen P.F., Dossing M., Hansen H., Kofoed K.F., Larsen K.R., et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax 2012, 67:296-301.
36. Infante M., Cavuto S., Lutman F., Brambilla G., Chiesa G., Ceresoli G., Passera E., Angeli E., Chiarenza M., Aranzulla G., et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am. J. Respir. Crit. Care Med. 2009, 180:445-453.
37. Pastorino U., Rossi M., Rosato V., Marchiano A., Sverzellati N., Morosi C., Fabbri A., Galeone C., Negri E., Sozzi G., et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur. J. Cancer Prev. 2012, 21:308-315.
38. van Klaveren R.J., Oudkerk M., Prokop M., Scholten E.T., Nackaerts K., Vernhout R., van Iersel C.A., van den Bergh K.A., van't Westeinde S., van der Aalst C., et al. Management of lung nodules detected by volume CT scanning. N. Engl. J. Med. 2009, 361:2221-2229.
39. Xu D.M., Gietema H., de Koning H., Vernhout R., Nackaerts K., Prokop M., Weenink C., Lammers J.W., Groen H., Oudkerk M., van Klaveren R. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer 2006, 54:177-184.
40. van Iersel C.A., de Koning H.J., Draisma G., Mali W.P., Scholten E.T., Nackaerts K., Prokop M., Habbema J.D., Oudkerk M., van Klaveren R.J. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int. J. Cancer 2007, 120:868-874.
41. Infante M., Cavuto S., Lutman F.R., Brambilla G., Chiesa G., Ceresoli G., Passera E., Angeli E., Chiarenza M., Aranzulla G., et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am. J. Respir. Crit. Care Med. 2009, 180:445-453.
42. Pastorino U., Rossi M., Rosato V., Marchiano A., Sverzellati N., Morosi C., Fabbri A., Galeone C., Negri E., Sozzi G., et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur. J. Cancer Prev. 2012, 21:308-315.
43. Field J.K. Perspective: the screening imperative. Nature 2014, 513:S7.
44. National Institute for Health and Clinical Excellence Guide to the Methods of Technology Appraisal 2008, NICE, London.
45. Black W.C., Gareen I.F., Soneji S.S., Sicks J.D., Keeler E.B., Aberle D.R., Naeim A., Church T.R., Silvestri G.A., Gorelick J., et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N. Engl. J. Med. 2014, 371:1793-1802.
46. Pyenson B.S., Henschke C.I., Yankelevitz D.F., Yip R., Dec E. Offering lung cancer screening to high-risk medicare beneficiaries saves lives and is cost-effective: an actuarial analysis. Am. Health Drug Benefits 2014, 7:272-282.
47. Whynes D.K. Could CT screening for lung cancer ever be cost effective in the United Kingdom?. Cost Eff. Resour. Alloc. 2008, 6:5.
48. Duffy S.W., Field J.K., Allgood P.C., Seigneurin A. Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom. Br. J. Cancer 2014, 110:1834-1840.